SEC Form 4 · accession 0001209191-15-005965
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Curtis Ruegg
Officer — EVP R&D and Tech Operations
Period of report
Jan 20, 2015
Accepted (ET)
Jan 22, 2015 · 7:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 20, 2015 | M | 1,000 | $2.55 | A | 15,106 | D | |
| Common Stock | Jan 20, 2015 | S | 1,000 | $17.25 | D | 14,106 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $2.55 | Jan 20, 2015 | M | 1,000 | D | — | Apr 29, 2018 | Common Stock | 1,000 | 170 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2014.
- F2The Option is fully vested as of January 1, 2012.